EAU 2025 | IP7-PACIFIC: multiparametric versus biparametric MRI in prostate cancer

Nikhil Mayor • 4 Mar 2025

EAU 2025

IP7-PACIFIC

Nikhil Mayor, MD, Imperial College London, London, UK, provides an overview of the IP7-PACIFIC trial (NCT05574647), a multicenter study assessing the clinical utility and cost-effectiveness of biparametric MRI (bpMRI) compared to multiparametric MRI (mpMRI) in prostate cancer detection. The trial also examines whether image-fusion targeted biopsy offers advantages over visual-registration biopsy. Findings will help refine guidelines for prostate cancer imaging and biopsy techniques. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.